Global Ketamine Therapy Market By Type of Therapy, By Indication, By Setting, By Region; Global Insights, Growth, Size, Comparative Analysis, Trends and Forecasts, 2023 – 2031

  • Industry: Healthcare
  • Report ID: TNR-110-1036
  • Number of Pages: 420
  • Table/Charts : Yes
  • December, 2023
  • Base Year : 2024
  • No. of Companies : 9+
  • No. of Countries : 29
  • Views : 10082
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Global Ketamine Therapy Market was Valued at US$ 1.38 Billion in 2022, Growing at an Estimated CAGR of 11.9% from 2023-2031

Ketamine therapy is a psychiatric treatment involving controlled administration of the anesthetic drug ketamine. Given in low doses, it’s used to alleviate symptoms of depression, anxiety, and certain mental health conditions. Its rapid effects and potential to target treatment-resistant cases make it a notable alternative in mental health care.

Intravenous (IV) ketamine therapy currently dominates the market due to its established efficacy and long-standing medical use. Surveys and studies consistently highlight the positive outcomes of IV ketamine in treating depression and certain mood disorders. Its direct administration into the bloodstream ensures rapid effects, making it a preferred choice.

COVID-19 Impact Analysis on Global Ketamine Therapy Market

Pre-COVID-19, the ketamine therapy market showed promise as a mental health treatment, with both intravenous and intranasal forms gaining traction. Post-COVID-19, the market adapted to pandemic challenges, with disruptions in healthcare access affecting patient reach. Telehealth gained prominence, but economic uncertainties impacted therapy availability and market dynamics.

Mental health professionals are seeking rapid relief through ketamine therapy stems owing to the pressing need to address treatment-resistant mental health disorders. Conventional treatments often take weeks to show results, leaving patients in distress. Recognizing the potential, psychiatrists, therapists, and other mental health providers are integrating ketamine therapy into their practices. Its rapid onset of action, often within hours, allows professionals to offer faster relief and symptom management for patients who may be in crisis or have exhausted traditional treatment options. This demand for innovative solutions aligns with ketamine therapy’s potential to reshape mental healthcare. A key restraint is the absence of standardized protocols and regulatory oversight. The lack of comprehensive regulations contributes to safety concerns and hesitancy among practitioners and patients, potentially limiting market growth.

Ketamine therapy significantly dominates the market for its effectiveness in treating depression. The therapy’s ability to provide quick and notable improvements in mood and overall well-being has positioned it as a leading choice for addressing depressive disorders.

North America dominated the global ketamine therapy market in 2022 due to its advanced healthcare infrastructure and early adoption. The US particularly leads in ketamine therapy integration, benefiting from a robust mental health industry and research initiatives.

Competitive Landscape: Global Ketamine Therapy Market

  • AbbVie Inc.
  • Actify Neurotherapies
  • Janssen Pharmaceutical Companies (Johnson & Johnson Services, Inc.)
  • Ketamine Clinics Los Angeles
  • Ketamine Research Institute
  • Ketamine Wellness Centers
  • Klarisana
  • Mindbloom, Inc.
  • Neuro Wellness Spa
  • Stella MSO LLC dba Field Trip Health
  • Other Industry Participants

Global Ketamine Therapy Market Scope

Report Specifications Details
Market Revenue in 2022 US$ 1.38 Billion
Market Size Forecast by 2031 US$ 3.74 Billion
Growth Rate (CAGR) 11.9%
Historic Data 2019 – 2021
Base Year for Estimation 2022
Forecast Period 2023 – 2031
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Type of Therapy, By Indication, By Setting, By Region
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players AbbVie Inc., Actify Neurotherapies, Janssen Pharmaceutical Companies (Johnson & Johnson Services, Inc.), Ketamine Clinics Los Angeles, Ketamine Research Institute, Ketamine Wellness Centers, Klarisana, Mindbloom, Inc., Neuro Wellness Spa, Stella MSO LLC dba Field Trip Health, Other Industry Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

Report Layout

Global Ketamine Therapy Market

By Type of Therapy

  • Intravenous (IV) Ketamine Therapy
  • Intranasal Ketamine Therapy
  • Oral Ketamine Therapy

By Indication

  • Depression
  • Anxiety Disorders
  • Chronic Pain
  • Substance Use Disorders

By Setting

  • Clinics
  • Hospitals
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2019 - 2021
1.2.2.Base Year: 2022
1.2.3.Forecast Years: 2023 – 2031
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Ketamine Therapy Market
6.Market Synopsis: Ketamine Therapy Market
7.Ketamine Therapy Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.2.4.Challenges
7.3.Trends in Ketamine Therapy Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Ketamine Therapy Market
7.6.Porter’s Five Force Analysis
8.Global Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
8.1.Overview
8.1.1.Global Ketamine Therapy Market Revenue (US$ Mn)
8.2.Global Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
8.2.1.Intravenous (IV) Ketamine Therapy
8.2.1.1.Definition
8.2.1.2.Market Estimation and Penetration, 2019 - 2022
8.2.1.3.Market Forecast, 2023 - 2031
8.2.1.4.Compound Annual Growth Rate (CAGR)
8.2.1.5.Regional Bifurcation
8.2.1.5.1.North America
8.2.1.5.1.1.Market Estimation, 2019 - 2022
8.2.1.5.1.2.Market Forecast, 2023 - 2031
8.2.1.5.2.Europe
8.2.1.5.2.1.Market Estimation, 2019 - 2022
8.2.1.5.2.2.Market Forecast, 2023 - 2031
8.2.1.5.3.Asia Pacific
8.2.1.5.3.1.Market Estimation, 2019 - 2022
8.2.1.5.3.2.Market Forecast, 2023 - 2031
8.2.1.5.4.Middle East and Africa
8.2.1.5.4.1.Market Estimation, 2019 - 2022
8.2.1.5.4.2.Market Forecast, 2023 - 2031
8.2.1.5.5.Latin America
8.2.1.5.5.1.Market Estimation, 2019 - 2022
8.2.1.5.5.2.Market Forecast, 2023 - 2031
8.2.2.Intranasal Ketamine Therapy
8.2.2.1.Definition
8.2.2.2.Market Estimation and Penetration, 2019 - 2022
8.2.2.3.Market Forecast, 2023 - 2031
8.2.2.4.Compound Annual Growth Rate (CAGR)
8.2.2.5.Regional Bifurcation
8.2.2.5.1.North America
8.2.2.5.1.1.Market Estimation, 2019 - 2022
8.2.2.5.1.2.Market Forecast, 2023 - 2031
8.2.2.5.2.Europe
8.2.2.5.2.1.Market Estimation, 2019 - 2022
8.2.2.5.2.2.Market Forecast, 2023 - 2031
8.2.2.5.3.Asia Pacific
8.2.2.5.3.1.Market Estimation, 2019 - 2022
8.2.2.5.3.2.Market Forecast, 2023 - 2031
8.2.2.5.4.Middle East and Africa
8.2.2.5.4.1.Market Estimation, 2019 - 2022
8.2.2.5.4.2.Market Forecast, 2023 - 2031
8.2.2.5.5.Latin America
8.2.2.5.5.1.Market Estimation, 2019 - 2022
8.2.2.5.5.2.Market Forecast, 2023 - 2031
8.2.3.Oral Ketamine Therapy
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2019 - 2022
8.2.3.3.Market Forecast, 2023 - 2031
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2019 - 2022
8.2.3.5.1.2.Market Forecast, 2023 - 2031
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2019 - 2022
8.2.3.5.2.2.Market Forecast, 2023 - 2031
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2019 - 2022
8.2.3.5.3.2.Market Forecast, 2023 - 2031
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2019 - 2022
8.2.3.5.4.2.Market Forecast, 2023 - 2031
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2019 - 2022
8.2.3.5.5.2.Market Forecast, 2023 - 2031
8.3.Key Segment for Channeling Investments
8.3.1.By Type of Therapy
9.Global Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
9.1.Overview
9.2.Global Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
9.2.1.Depression
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2019 - 2022
9.2.1.3.Market Forecast, 2023 - 2031
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2019 - 2022
9.2.1.5.1.2.Market Forecast, 2023 - 2031
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2019 - 2022
9.2.1.5.2.2.Market Forecast, 2023 - 2031
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2019 - 2022
9.2.1.5.3.2.Market Forecast, 2023 - 2031
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2019 - 2022
9.2.1.5.4.2.Market Forecast, 2023 - 2031
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2019 - 2022
9.2.1.5.5.2.Market Forecast, 2023 - 2031
9.2.2.Anxiety Disorders
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2019 - 2022
9.2.2.3.Market Forecast, 2023 - 2031
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2019 - 2022
9.2.2.5.1.2.Market Forecast, 2023 - 2031
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2019 - 2022
9.2.2.5.2.2.Market Forecast, 2023 - 2031
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2019 - 2022
9.2.2.5.3.2.Market Forecast, 2023 - 2031
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2019 - 2022
9.2.2.5.4.2.Market Forecast, 2023 - 2031
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2019 - 2022
9.2.2.5.5.2.Market Forecast, 2023 - 2031
9.2.3.Chronic Pain
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2019 - 2022
9.2.3.3.Market Forecast, 2023 - 2031
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2019 - 2022
9.2.3.5.1.2.Market Forecast, 2023 - 2031
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2019 - 2022
9.2.3.5.2.2.Market Forecast, 2023 - 2031
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2019 - 2022
9.2.3.5.3.2.Market Forecast, 2023 - 2031
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2019 - 2022
9.2.3.5.4.2.Market Forecast, 2023 - 2031
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2019 - 2022
9.2.3.5.5.2.Market Forecast, 2023 - 2031
9.2.4.Substance Use Disorders
9.2.4.1.Definition
9.2.4.2.Market Estimation and Penetration, 2019 - 2022
9.2.4.3.Market Forecast, 2023 - 2031
9.2.4.4.Compound Annual Growth Rate (CAGR)
9.2.4.5.Regional Bifurcation
9.2.4.5.1.North America
9.2.4.5.1.1.Market Estimation, 2019 - 2022
9.2.4.5.1.2.Market Forecast, 2023 - 2031
9.2.4.5.2.Europe
9.2.4.5.2.1.Market Estimation, 2019 - 2022
9.2.4.5.2.2.Market Forecast, 2023 - 2031
9.2.4.5.3.Asia Pacific
9.2.4.5.3.1.Market Estimation, 2019 - 2022
9.2.4.5.3.2.Market Forecast, 2023 - 2031
9.2.4.5.4.Middle East and Africa
9.2.4.5.4.1.Market Estimation, 2019 - 2022
9.2.4.5.4.2.Market Forecast, 2023 - 2031
9.2.4.5.5.Latin America
9.2.4.5.5.1.Market Estimation, 2019 - 2022
9.2.4.5.5.2.Market Forecast, 2023 - 2031
9.3.Key Segment for Channeling Investments
9.3.1.By Indication
10.Global Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
10.1.Overview
10.2.Global Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
10.2.1.Clinics
10.2.1.1.Definition
10.2.1.2.Market Estimation and Penetration, 2019 - 2022
10.2.1.3.Market Forecast, 2023 - 2031
10.2.1.4.Compound Annual Growth Rate (CAGR)
10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2019 - 2022
10.2.1.5.1.2.Market Forecast, 2023 - 2031
10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2019 - 2022
10.2.1.5.2.2.Market Forecast, 2023 - 2031
10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2019 - 2022
10.2.1.5.3.2.Market Forecast, 2023 - 2031
10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2019 - 2022
10.2.1.5.4.2.Market Forecast, 2023 - 2031
10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2019 - 2022
10.2.1.5.5.2.Market Forecast, 2023 - 2031
10.2.2.Hospitals
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2019 - 2022
10.2.2.3.Market Forecast, 2023 - 2031
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2019 - 2022
10.2.2.5.1.2.Market Forecast, 2023 - 2031
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2019 - 2022
10.2.2.5.2.2.Market Forecast, 2023 - 2031
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2019 - 2022
10.2.2.5.3.2.Market Forecast, 2023 - 2031
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2019 - 2022
10.2.2.5.4.2.Market Forecast, 2023 - 2031
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2019 - 2022
10.2.2.5.5.2.Market Forecast, 2023 - 2031
10.2.3.Others
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2019 - 2022
10.2.3.3.Market Forecast, 2023 - 2031
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2019 - 2022
10.2.3.5.1.2.Market Forecast, 2023 - 2031
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2019 - 2022
10.2.3.5.2.2.Market Forecast, 2023 - 2031
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2019 - 2022
10.2.3.5.3.2.Market Forecast, 2023 - 2031
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2019 - 2022
10.2.3.5.4.2.Market Forecast, 2023 - 2031
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2019 - 2022
10.2.3.5.5.2.Market Forecast, 2023 - 2031
10.3.Key Segment for Channeling Investments
10.3.1.By Setting
11.North America Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
11.1.Overview
11.1.1.North America Ketamine Therapy Market Revenue (US$ Mn)
11.2.North America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
11.2.1.Intravenous (IV) Ketamine Therapy
11.2.2.Intranasal Ketamine Therapy
11.2.3.Oral Ketamine Therapy
11.3.North America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
11.3.1.Depression
11.3.2.Anxiety Disorders
11.3.3.Chronic Pain
11.3.4.Substance Use Disorders
11.4.North America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
11.4.1.Clinics
11.4.2.Hospitals
11.4.3.Others
11.5.North America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1.U.S
11.5.1.1.U.S Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
11.5.1.1.1.Intravenous (IV) Ketamine Therapy
11.5.1.1.2.Intranasal Ketamine Therapy
11.5.1.1.3.Oral Ketamine Therapy
11.5.1.2.U.S Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.1.2.1.Depression
11.5.1.2.2.Anxiety Disorders
11.5.1.2.3.Chronic Pain
11.5.1.2.4.Substance Use Disorders
11.5.1.3.U.S Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
11.5.1.3.1.Clinics
11.5.1.3.2.Hospitals
11.5.1.3.3.Others
11.5.2.Canada
11.5.2.1.Canada Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
11.5.2.1.1.Intravenous (IV) Ketamine Therapy
11.5.2.1.2.Intranasal Ketamine Therapy
11.5.2.1.3.Oral Ketamine Therapy
11.5.2.2.Canada Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.2.2.1.Depression
11.5.2.2.2.Anxiety Disorders
11.5.2.2.3.Chronic Pain
11.5.2.2.4.Substance Use Disorders
11.5.2.3.Canada Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
11.5.2.3.1.Clinics
11.5.2.3.2.Hospitals
11.5.2.3.3.Others
11.5.3.Mexico
11.5.3.1.Mexico Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
11.5.3.1.1.Intravenous (IV) Ketamine Therapy
11.5.3.1.2.Intranasal Ketamine Therapy
11.5.3.1.3.Oral Ketamine Therapy
11.5.3.2.Mexico Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.3.2.1.Depression
11.5.3.2.2.Anxiety Disorders
11.5.3.2.3.Chronic Pain
11.5.3.2.4.Substance Use Disorders
11.5.3.3.Mexico Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
11.5.3.3.1.Clinics
11.5.3.3.2.Hospitals
11.5.3.3.3.Others
11.5.4.Rest of North America
11.5.4.1.Rest of North America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
11.5.4.1.1.Intravenous (IV) Ketamine Therapy
11.5.4.1.2.Intranasal Ketamine Therapy
11.5.4.1.3.Oral Ketamine Therapy
11.5.4.2.Rest of North America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.4.2.1.Depression
11.5.4.2.2.Anxiety Disorders
11.5.4.2.3.Chronic Pain
11.5.4.2.4.Substance Use Disorders
11.5.4.3.Rest of North America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
11.5.4.3.1.Clinics
11.5.4.3.2.Hospitals
11.5.4.3.3.Others
11.6.Key Segment for Channeling Investments
11.6.1.By Country
11.6.2.By Type of Therapy
11.6.3.By Indication
11.6.4.By Setting
12.Europe Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
12.1.Overview
12.1.1.Europe Ketamine Therapy Market Revenue (US$ Mn)
12.2.Europe Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.2.1.Intravenous (IV) Ketamine Therapy
12.2.2.Intranasal Ketamine Therapy
12.2.3.Oral Ketamine Therapy
12.3.Europe Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.3.1.Depression
12.3.2.Anxiety Disorders
12.3.3.Chronic Pain
12.3.4.Substance Use Disorders
12.4.Europe Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.4.1.Clinics
12.4.2.Hospitals
12.4.3.Others
12.5.Europe Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1.France
12.5.1.1.France Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.1.1.1.Intravenous (IV) Ketamine Therapy
12.5.1.1.2.Intranasal Ketamine Therapy
12.5.1.1.3.Oral Ketamine Therapy
12.5.1.2.France Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.1.2.1.Depression
12.5.1.2.2.Anxiety Disorders
12.5.1.2.3.Chronic Pain
12.5.1.2.4.Substance Use Disorders
12.5.1.3.France Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.1.3.1.Clinics
12.5.1.3.2.Hospitals
12.5.1.3.3.Others
12.5.2.The UK
12.5.2.1.The UK Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.2.1.1.Intravenous (IV) Ketamine Therapy
12.5.2.1.2.Intranasal Ketamine Therapy
12.5.2.1.3.Oral Ketamine Therapy
12.5.2.2.The UK Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.2.2.1.Depression
12.5.2.2.2.Anxiety Disorders
12.5.2.2.3.Chronic Pain
12.5.2.2.4.Substance Use Disorders
12.5.2.3.The UK Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.2.3.1.Clinics
12.5.2.3.2.Hospitals
12.5.2.3.3.Others
12.5.3.Spain
12.5.3.1.Spain Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.3.1.1.Intravenous (IV) Ketamine Therapy
12.5.3.1.2.Intranasal Ketamine Therapy
12.5.3.1.3.Oral Ketamine Therapy
12.5.3.2.Spain Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.3.2.1.Depression
12.5.3.2.2.Anxiety Disorders
12.5.3.2.3.Chronic Pain
12.5.3.2.4.Substance Use Disorders
12.5.3.3.Spain Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.3.3.1.Clinics
12.5.3.3.2.Hospitals
12.5.3.3.3.Others
12.5.4.Germany
12.5.4.1.Germany Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.4.1.1.Intravenous (IV) Ketamine Therapy
12.5.4.1.2.Intranasal Ketamine Therapy
12.5.4.1.3.Oral Ketamine Therapy
12.5.4.2.Germany Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.4.2.1.Depression
12.5.4.2.2.Anxiety Disorders
12.5.4.2.3.Chronic Pain
12.5.4.2.4.Substance Use Disorders
12.5.4.3.Germany Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.4.3.1.Clinics
12.5.4.3.2.Hospitals
12.5.4.3.3.Others
12.5.5.Italy
12.5.5.1.Italy Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.5.1.1.Intravenous (IV) Ketamine Therapy
12.5.5.1.2.Intranasal Ketamine Therapy
12.5.5.1.3.Oral Ketamine Therapy
12.5.5.2.Italy Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.5.2.1.Depression
12.5.5.2.2.Anxiety Disorders
12.5.5.2.3.Chronic Pain
12.5.5.2.4.Substance Use Disorders
12.5.5.3.Italy Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.5.3.1.Clinics
12.5.5.3.2.Hospitals
12.5.5.3.3.Others
12.5.6.Nordic Countries
12.5.6.1.Nordic Countries Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.6.1.1.Intravenous (IV) Ketamine Therapy
12.5.6.1.2.Intranasal Ketamine Therapy
12.5.6.1.3.Oral Ketamine Therapy
12.5.6.2.Nordic Countries Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.6.2.1.Depression
12.5.6.2.2.Anxiety Disorders
12.5.6.2.3.Chronic Pain
12.5.6.2.4.Substance Use Disorders
12.5.6.3.Nordic Countries Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.6.3.1.Clinics
12.5.6.3.2.Hospitals
12.5.6.3.3.Others
12.5.6.4.Nordic Countries Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1.Denmark
12.5.6.4.2.Finland
12.5.6.4.3.Iceland
12.5.6.4.4.Sweden
12.5.6.4.5.Norway
12.5.7.Benelux Union
12.5.7.1.Benelux Union Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.7.1.1.Intravenous (IV) Ketamine Therapy
12.5.7.1.2.Intranasal Ketamine Therapy
12.5.7.1.3.Oral Ketamine Therapy
12.5.7.2.Benelux Union Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.7.2.1.Depression
12.5.7.2.2.Anxiety Disorders
12.5.7.2.3.Chronic Pain
12.5.7.2.4.Substance Use Disorders
12.5.7.3.Benelux Union Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.7.3.1.Clinics
12.5.7.3.2.Hospitals
12.5.7.3.3.Others
12.5.7.4.Benelux Union Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1.Belgium
12.5.7.4.2.The Netherlands
12.5.7.4.3.Luxembourg
12.5.8.Rest of Europe
12.5.8.1.Rest of Europe Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
12.5.8.1.1.Intravenous (IV) Ketamine Therapy
12.5.8.1.2.Intranasal Ketamine Therapy
12.5.8.1.3.Oral Ketamine Therapy
12.5.8.2.Rest of Europe Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.8.2.1.Depression
12.5.8.2.2.Anxiety Disorders
12.5.8.2.3.Chronic Pain
12.5.8.2.4.Substance Use Disorders
12.5.8.3.Rest of Europe Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
12.5.8.3.1.Clinics
12.5.8.3.2.Hospitals
12.5.8.3.3.Others
12.6.Key Segment for Channeling Investments
12.6.1.By Country
12.6.2.By Type of Therapy
12.6.3.By Indication
12.6.4.By Setting
13.Asia Pacific Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
13.1.Overview
13.1.1.Asia Pacific Ketamine Therapy Market Revenue (US$ Mn)
13.2.Asia Pacific Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.2.1.Intravenous (IV) Ketamine Therapy
13.2.2.Intranasal Ketamine Therapy
13.2.3.Oral Ketamine Therapy
13.3.Asia Pacific Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.3.1.Depression
13.3.2.Anxiety Disorders
13.3.3.Chronic Pain
13.3.4.Substance Use Disorders
13.4.Asia Pacific Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.4.1.Clinics
13.4.2.Hospitals
13.4.3.Others
13.5.Asia Pacific Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1.China
13.5.1.1.China Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.1.1.1.Intravenous (IV) Ketamine Therapy
13.5.1.1.2.Intranasal Ketamine Therapy
13.5.1.1.3.Oral Ketamine Therapy
13.5.1.2.China Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.1.2.1.Depression
13.5.1.2.2.Anxiety Disorders
13.5.1.2.3.Chronic Pain
13.5.1.2.4.Substance Use Disorders
13.5.1.3.China Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.1.3.1.Clinics
13.5.1.3.2.Hospitals
13.5.1.3.3.Others
13.5.2.Japan
13.5.2.1.Japan Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.2.1.1.Intravenous (IV) Ketamine Therapy
13.5.2.1.2.Intranasal Ketamine Therapy
13.5.2.1.3.Oral Ketamine Therapy
13.5.2.2.Japan Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.2.2.1.Depression
13.5.2.2.2.Anxiety Disorders
13.5.2.2.3.Chronic Pain
13.5.2.2.4.Substance Use Disorders
13.5.2.3.Japan Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.2.3.1.Clinics
13.5.2.3.2.Hospitals
13.5.2.3.3.Others
13.5.3.India
13.5.3.1.India Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.3.1.1.Intravenous (IV) Ketamine Therapy
13.5.3.1.2.Intranasal Ketamine Therapy
13.5.3.1.3.Oral Ketamine Therapy
13.5.3.2.India Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.3.2.1.Depression
13.5.3.2.2.Anxiety Disorders
13.5.3.2.3.Chronic Pain
13.5.3.2.4.Substance Use Disorders
13.5.3.3.India Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.3.3.1.Clinics
13.5.3.3.2.Hospitals
13.5.3.3.3.Others
13.5.4.New Zealand
13.5.4.1.New Zealand Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.4.1.1.Intravenous (IV) Ketamine Therapy
13.5.4.1.2.Intranasal Ketamine Therapy
13.5.4.1.3.Oral Ketamine Therapy
13.5.4.2.New Zealand Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.4.2.1.Depression
13.5.4.2.2.Anxiety Disorders
13.5.4.2.3.Chronic Pain
13.5.4.2.4.Substance Use Disorders
13.5.4.3.New Zealand Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.4.3.1.Clinics
13.5.4.3.2.Hospitals
13.5.4.3.3.Others
13.5.5.Australia
13.5.5.1.Australia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.5.1.1.Intravenous (IV) Ketamine Therapy
13.5.5.1.2.Intranasal Ketamine Therapy
13.5.5.1.3.Oral Ketamine Therapy
13.5.5.2.Australia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.5.2.1.Depression
13.5.5.2.2.Anxiety Disorders
13.5.5.2.3.Chronic Pain
13.5.5.2.4.Substance Use Disorders
13.5.5.3.Australia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.5.3.1.Clinics
13.5.5.3.2.Hospitals
13.5.5.3.3.Others
13.5.6.South Korea
13.5.6.1.South Korea Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.6.1.1.Intravenous (IV) Ketamine Therapy
13.5.6.1.2.Intranasal Ketamine Therapy
13.5.6.1.3.Oral Ketamine Therapy
13.5.6.2.South Korea Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.6.2.1.Depression
13.5.6.2.2.Anxiety Disorders
13.5.6.2.3.Chronic Pain
13.5.6.2.4.Substance Use Disorders
13.5.6.3.South Korea Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.6.3.1.Clinics
13.5.6.3.2.Hospitals
13.5.6.3.3.Others
13.5.7.Southeast Asia
13.5.7.1.Southeast Asia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.7.1.1.Intravenous (IV) Ketamine Therapy
13.5.7.1.2.Intranasal Ketamine Therapy
13.5.7.1.3.Oral Ketamine Therapy
13.5.7.2.Southeast Asia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.7.2.1.Depression
13.5.7.2.2.Anxiety Disorders
13.5.7.2.3.Chronic Pain
13.5.7.2.4.Substance Use Disorders
13.5.7.3.Southeast Asia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.7.3.1.Clinics
13.5.7.3.2.Hospitals
13.5.7.3.3.Others
13.5.7.4.Southeast Asia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1.Indonesia
13.5.7.4.2.Thailand
13.5.7.4.3.Malaysia
13.5.7.4.4.Singapore
13.5.7.4.5.Rest of Southeast Asia
13.5.8.Rest of Asia Pacific
13.5.8.1.Rest of Asia Pacific Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
13.5.8.1.1.Intravenous (IV) Ketamine Therapy
13.5.8.1.2.Intranasal Ketamine Therapy
13.5.8.1.3.Oral Ketamine Therapy
13.5.8.2.Rest of Asia Pacific Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.8.2.1.Depression
13.5.8.2.2.Anxiety Disorders
13.5.8.2.3.Chronic Pain
13.5.8.2.4.Substance Use Disorders
13.5.8.3.Rest of Asia Pacific Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
13.5.8.3.1.Clinics
13.5.8.3.2.Hospitals
13.5.8.3.3.Others
13.6.Key Segment for Channeling Investments
13.6.1.By Country
13.6.2.By Type of Therapy
13.6.3.By Indication
13.6.4.By Setting
14.Middle East and Africa Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
14.1.Overview
14.1.1.Middle East and Africa Ketamine Therapy Market Revenue (US$ Mn)
14.2.Middle East and Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
14.2.1.Intravenous (IV) Ketamine Therapy
14.2.2.Intranasal Ketamine Therapy
14.2.3.Oral Ketamine Therapy
14.3.Middle East and Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
14.3.1.Depression
14.3.2.Anxiety Disorders
14.3.3.Chronic Pain
14.3.4.Substance Use Disorders
14.4.Middle East and Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
14.4.1.Clinics
14.4.2.Hospitals
14.4.3.Others
14.5.Middle East and Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1.Saudi Arabia
14.5.1.1.Saudi Arabia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
14.5.1.1.1.Intravenous (IV) Ketamine Therapy
14.5.1.1.2.Intranasal Ketamine Therapy
14.5.1.1.3.Oral Ketamine Therapy
14.5.1.2.Saudi Arabia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.1.2.1.Depression
14.5.1.2.2.Anxiety Disorders
14.5.1.2.3.Chronic Pain
14.5.1.2.4.Substance Use Disorders
14.5.1.3.Saudi Arabia Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
14.5.1.3.1.Clinics
14.5.1.3.2.Hospitals
14.5.1.3.3.Others
14.5.2.UAE
14.5.2.1.UAE Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
14.5.2.1.1.Intravenous (IV) Ketamine Therapy
14.5.2.1.2.Intranasal Ketamine Therapy
14.5.2.1.3.Oral Ketamine Therapy
14.5.2.2.UAE Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.2.2.1.Depression
14.5.2.2.2.Anxiety Disorders
14.5.2.2.3.Chronic Pain
14.5.2.2.4.Substance Use Disorders
14.5.2.3.UAE Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
14.5.2.3.1.Clinics
14.5.2.3.2.Hospitals
14.5.2.3.3.Others
14.5.3.Egypt
14.5.3.1.Egypt Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
14.5.3.1.1.Intravenous (IV) Ketamine Therapy
14.5.3.1.2.Intranasal Ketamine Therapy
14.5.3.1.3.Oral Ketamine Therapy
14.5.3.2.Egypt Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.3.2.1.Depression
14.5.3.2.2.Anxiety Disorders
14.5.3.2.3.Chronic Pain
14.5.3.2.4.Substance Use Disorders
14.5.3.3.Egypt Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
14.5.3.3.1.Clinics
14.5.3.3.2.Hospitals
14.5.3.3.3.Others
14.5.4.Kuwait
14.5.4.1.Kuwait Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
14.5.4.1.1.Intravenous (IV) Ketamine Therapy
14.5.4.1.2.Intranasal Ketamine Therapy
14.5.4.1.3.Oral Ketamine Therapy
14.5.4.2.Kuwait Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.4.2.1.Depression
14.5.4.2.2.Anxiety Disorders
14.5.4.2.3.Chronic Pain
14.5.4.2.4.Substance Use Disorders
14.5.4.3.Kuwait Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
14.5.4.3.1.Clinics
14.5.4.3.2.Hospitals
14.5.4.3.3.Others
14.5.5.South Africa
14.5.5.1.South Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
14.5.5.1.1.Intravenous (IV) Ketamine Therapy
14.5.5.1.2.Intranasal Ketamine Therapy
14.5.5.1.3.Oral Ketamine Therapy
14.5.5.2.South Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.5.2.1.Depression
14.5.5.2.2.Anxiety Disorders
14.5.5.2.3.Chronic Pain
14.5.5.2.4.Substance Use Disorders
14.5.5.3.South Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
14.5.5.3.1.Clinics
14.5.5.3.2.Hospitals
14.5.5.3.3.Others
14.5.6.Rest of Middle East & Africa
14.5.6.1.Rest of Middle East & Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
14.5.6.1.1.Intravenous (IV) Ketamine Therapy
14.5.6.1.2.Intranasal Ketamine Therapy
14.5.6.1.3.Oral Ketamine Therapy
14.5.6.2.Rest of Middle East & Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.6.2.1.Depression
14.5.6.2.2.Anxiety Disorders
14.5.6.2.3.Chronic Pain
14.5.6.2.4.Substance Use Disorders
14.5.6.3.Rest of Middle East & Africa Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
14.5.6.3.1.Clinics
14.5.6.3.2.Hospitals
14.5.6.3.3.Others
14.6.Key Segment for Channeling Investments
14.6.1.By Country
14.6.2.By Type of Therapy
14.6.3.By Indication
14.6.4.By Setting
15.Latin America Ketamine Therapy Market Analysis and Forecasts, 2023 - 2031
15.1.Overview
15.1.1.Latin America Ketamine Therapy Market Revenue (US$ Mn)
15.2.Latin America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
15.2.1.Intravenous (IV) Ketamine Therapy
15.2.2.Intranasal Ketamine Therapy
15.2.3.Oral Ketamine Therapy
15.3.Latin America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
15.3.1.Depression
15.3.2.Anxiety Disorders
15.3.3.Chronic Pain
15.3.4.Substance Use Disorders
15.4.Latin America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
15.4.1.Clinics
15.4.2.Hospitals
15.4.3.Others
15.5.Latin America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1.Brazil
15.5.1.1.Brazil Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
15.5.1.1.1.Intravenous (IV) Ketamine Therapy
15.5.1.1.2.Intranasal Ketamine Therapy
15.5.1.1.3.Oral Ketamine Therapy
15.5.1.2.Brazil Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.1.2.1.Depression
15.5.1.2.2.Anxiety Disorders
15.5.1.2.3.Chronic Pain
15.5.1.2.4.Substance Use Disorders
15.5.1.3.Brazil Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
15.5.1.3.1.Clinics
15.5.1.3.2.Hospitals
15.5.1.3.3.Others
15.5.2.Argentina
15.5.2.1.Argentina Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
15.5.2.1.1.Intravenous (IV) Ketamine Therapy
15.5.2.1.2.Intranasal Ketamine Therapy
15.5.2.1.3.Oral Ketamine Therapy
15.5.2.2.Argentina Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.2.2.1.Depression
15.5.2.2.2.Anxiety Disorders
15.5.2.2.3.Chronic Pain
15.5.2.2.4.Substance Use Disorders
15.5.2.3.Argentina Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
15.5.2.3.1.Clinics
15.5.2.3.2.Hospitals
15.5.2.3.3.Others
15.5.3.Rest of Latin America
15.5.3.1.Rest of Latin America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Type of Therapy
15.5.3.1.1.Intravenous (IV) Ketamine Therapy
15.5.3.1.2.Intranasal Ketamine Therapy
15.5.3.1.3.Oral Ketamine Therapy
15.5.3.2.Rest of Latin America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.3.2.1.Depression
15.5.3.2.2.Anxiety Disorders
15.5.3.2.3.Chronic Pain
15.5.3.2.4.Substance Use Disorders
15.5.3.3.Rest of Latin America Ketamine Therapy Market Revenue (US$ Mn) and Forecasts, By Setting
15.5.3.3.1.Clinics
15.5.3.3.2.Hospitals
15.5.3.3.3.Others
15.6.Key Segment for Channeling Investments
15.6.1.By Country
15.6.2.By Type of Therapy
15.6.3.By Indication
15.6.4.By Setting
16.Competitive Benchmarking
16.1.Market Share Analysis, 2022
16.2.Global Presence and Growth Strategies
16.2.1.Mergers and Acquisitions
16.2.2.Product Launches
16.2.3.Investments Trends
16.2.4.R&D Initiatives
17.Player Profiles
17.1.AbbVie Inc.
17.1.1.Company Details
17.1.2.Company Overview
17.1.3.Product Offerings
17.1.4.Key Developments
17.1.5.Financial Analysis
17.1.6.SWOT Analysis
17.1.7.Business Strategies
17.2.Actify Neurotherapies
17.2.1.Company Details
17.2.2.Company Overview
17.2.3.Product Offerings
17.2.4.Key Developments
17.2.5.Financial Analysis
17.2.6.SWOT Analysis
17.2.7.Business Strategies
17.3.Janssen Pharmaceutical Companies (Johnson & Johnson Services, Inc.)
17.3.1.Company Details
17.3.2.Company Overview
17.3.3.Product Offerings
17.3.4.Key Developments
17.3.5.Financial Analysis
17.3.6.SWOT Analysis
17.3.7.Business Strategies
17.4.Ketamine Clinics Los Angeles
17.4.1.Company Details
17.4.2.Company Overview
17.4.3.Product Offerings
17.4.4.Key Developments
17.4.5.Financial Analysis
17.4.6.SWOT Analysis
17.4.7.Business Strategies
17.5.Ketamine Research Institute
17.5.1.Company Details
17.5.2.Company Overview
17.5.3.Product Offerings
17.5.4.Key Developments
17.5.5.Financial Analysis
17.5.6.SWOT Analysis
17.5.7.Business Strategies
17.6.Ketamine Wellness Centers
17.6.1.Company Details
17.6.2.Company Overview
17.6.3.Product Offerings
17.6.4.Key Developments
17.6.5.Financial Analysis
17.6.6.SWOT Analysis
17.6.7.Business Strategies
17.7.Klarisana
17.7.1.Company Details
17.7.2.Company Overview
17.7.3.Product Offerings
17.7.4.Key Developments
17.7.5.Financial Analysis
17.7.6.SWOT Analysis
17.7.7.Business Strategies
17.8.Mindbloom, Inc.
17.8.1.Company Details
17.8.2.Company Overview
17.8.3.Product Offerings
17.8.4.Key Developments
17.8.5.Financial Analysis
17.8.6.SWOT Analysis
17.8.7.Business Strategies
17.9.Neuro Wellness Spa
17.9.1.Company Details
17.9.2.Company Overview
17.9.3.Product Offerings
17.9.4.Key Developments
17.9.5.Financial Analysis
17.9.6.SWOT Analysis
17.9.7.Business Strategies
17.10.Stella MSO LLC dba Field Trip Health
17.10.1.Company Details
17.10.2.Company Overview
17.10.3.Product Offerings
17.10.4.Key Developments
17.10.5.Financial Analysis
17.10.6.SWOT Analysis
17.10.7.Business Strategies
17.11.Other Market Participants
18.Key Findings

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion

**Exclusive for Multi-User and Enterprise User.  

.

Global Ketamine Therapy Market

By Type of Therapy

 Intravenous (IV) Ketamine Therapy
 Intranasal Ketamine Therapy
 Oral Ketamine Therapy

By Indication

 Depression
 Anxiety Disorders
 Chronic Pain
 Substance Use Disorders

By Setting

 Clinics
 Hospitals
 Others

By Region

 North America (U.S., Canada, Mexico, Rest of North America)
 Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
 Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
 Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
 Latin America (Brazil, Argentina, Rest of Latin America)

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion

**Exclusive for Multi-User and Enterprise User.

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers. Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues. Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts. Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here's a breakdown of our data validation processes and the stakeholders we engage with during our primary research:
  • Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
  • Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
  • Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
  • In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.
The forecasts we provide are based on a comprehensive assessment of various factors, including:
  • Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market's evolution.
  • Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
  • Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
  • Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
  • New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
  • Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
  • End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
  • Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
  • Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market's historical performance.
Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It's crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.    

Procure Comprehensive Study of

Global Ketamine Therapy Market

Online Only

  • Online Access
  • Read Only File
  • Validity 3 Months
  • Print, Copy, Paste & Download
  • PPT, Excel
  • Cost-Free Report in the Next Update
$3300
Buy Now

Single User

  • Access to One User on One System
  • Read Only File
  • Validity 6 Months
  • Limited Print,Copy, Paste
  • PPT, Excel
  • Cost-Free Report in the Next Update
$4200
Buy Now

Multi User

  • Access to Fiver Users
  • PDF File
  • Validity 1 Year
  • Upto FivePrints
  • Cost-Free Report in the Next Update
  • PPT, Excel
$6000
Buy Now

Enterprise User

  • Access to Unlimited Users
  • PDF, PPT, Excel
  • Unlimited Validity, Prints&Downloads
  • 1 Hour Cost-Free & Dedicated Analyst Support
  • 10% Cost-Free Customization
  • Cost-Free Report Update Twice in a Year
  • Recommendations for Business Strategies
  • Authorization to Quote TNR, The Niche Research
$7300
Buy Now

Library Access

  • Online Access to Content Publications
  • Access Player Profiles Online
  • Get Immediate Access to Newly Added Content
  • Acquire 12 PDF Downloads
  • Acquire 5 Excel Data Sets
  • Gain Access to 290+ PDFs of Company Profiles
  • Round-the-clock Email and Phone Assistance
  • Dashboard Usage and Trends
  • Renewal & Upgrade Assistance
  • Assessing Customization Options and Alerts for New Reports
$10788
Buy Now
*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Why TNR The Niche Research?

  • Unwavering Commitment to Excellence

  • Veteran Team of Researchers

  • Accurate and Timely Insights

  • Ethical Practices and Customized Service

  • Uninterrupted Availability Around the Clock

Scroll to Top